2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Neoplasms
9
Breast Neoplasms
8
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Endometrial Neoplasms
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Interventions
apatinib
9
Paclitaxel
9
Capecitabine
7
Oxaliplatin
6
camrelizumab
5
Cisplatin
5
S 1 (combination)
4
Fluorouracil
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
titanium silicide
2
Leucovorin
2
Drug Therapy
2
vorolanib
1
trifluridine tipiracil drug combination
1
tipiracil
1
spartalizumab
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
lobaplatin
1
linrodostat
1
ezogabine
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
Trifluridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Gastric Cancer
×
rucaparib
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts